SCHEMBL12149856

SCHEMBL12149856

COc1ccc(OCc2cccc3ccccc23)c(C(=O)O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 2/20 0.60
▸ PARP15 Q460N3 1/20 0.60
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ FDPS P14324 1/20 0.56
▸ KDM4E B2RXH2 3/20 0.54
▸ ALDH1A1 P00352 2/20 0.54
▸ POLB P06746 1/20 0.53
▸ KEAP1 Q14145 1/20 0.52
▸ NFE2L2 Q16236 1/20 0.52
▸ GAA P10253 1/20 0.50
▸ FFAR1 O14842 1/20 0.50
▸ AKR1B1 P15121 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ MCL1 Q07820 1/20 0.49
▸ MTNR1A P48039 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ FOLH1 Q04609 1/20 0.48
▸ CDC25B P30305 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12149861 0.91 PARP10 (0.67) PARP10PARP15MEN1KMT2AFDPS
SCHEMBL12149845 0.87 MEN1 (0.60) PARP10PARP15MEN1KMT2AFDPS
SCHEMBL12149695 0.85 FDPS (0.68) PARP10PARP15MEN1KMT2AFDPS
SCHEMBL12149601 0.85 FDPS (0.68) PARP10PARP15MEN1KMT2AFDPS
SCHEMBL12149847 0.82 MRGPRX4 (0.61) MEN1KMT2AFDPSALDH1A1POLB
SCHEMBL12149587 0.82 FDPS (0.70) PARP10PARP15MEN1KMT2AFDPS
SCHEMBL1375050 0.82 KMT2A (0.76) PARP10PARP15MEN1KMT2AFDPS
SCHEMBL7906854 0.81 NPC1 (0.60) PARP10PARP15MEN1KMT2AFDPS
SCHEMBL1647498 0.80 FOLH1 (0.63) KDM4EALDH1A1POLBGAAL3MBTL1
SCHEMBL12149578 0.80 FDPS (0.64) PARP10PARP15MEN1KMT2AFDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2011-11-24 — — US disclosed
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2011-11-24 — — US disclosed
WO-2010043584-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS NOVARTIS AG (CH) 2010-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288057-A1 SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS FDPS, GGPS1, COASY PARP10 1018/4885PARP15 521/4885MEN1 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback